Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Other Accumulated Expenses (2016 - 2017)

Historic Other Accumulated Expenses for Amicus Therapeutics (FOLD) over the last 6 years, with Q4 2017 value amounting to $5.4 million.

  • Amicus Therapeutics' Other Accumulated Expenses rose 13602.62% to $5.4 million in Q4 2017 from the same period last year, while for Dec 2017 it was $5.4 million, marking a year-over-year increase of 13602.62%. This contributed to the annual value of $5.4 million for FY2017, which is 13602.62% up from last year.
  • Latest data reveals that Amicus Therapeutics reported Other Accumulated Expenses of $5.4 million as of Q4 2017, which was up 13602.62% from $2.3 million recorded in Q4 2016.
  • In the past 5 years, Amicus Therapeutics' Other Accumulated Expenses ranged from a high of $5.4 million in Q4 2017 and a low of $275000.0 during Q4 2013
  • Its 4-year average for Other Accumulated Expenses is $1.7 million, with a median of $679500.0 in 2014.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first surged by 5109.89% in 2013, then surged by 16472.73% in 2014.
  • Quarter analysis of 4 years shows Amicus Therapeutics' Other Accumulated Expenses stood at $275000.0 in 2013, then soared by 164.73% to $728000.0 in 2014, then soared by 214.56% to $2.3 million in 2016, then skyrocketed by 136.03% to $5.4 million in 2017.
  • Its last three reported values are $5.4 million in Q4 2017, $2.3 million for Q4 2016, and $607000.0 during Q3 2016.